Settlement Reached in Class Action Over Tracleer and Bosentan Purchases

Settlement Announced for Tracleer and Bosentan Purchasers

The United States District Court for the District of Maryland has officially approved a settlement in a significant class action lawsuit involving Tracleer and Bosentan. This settlement could potentially benefit many individuals and organizations that have purchased or reimbursed these medications during a specified period.

Overview of the Lawsuit

The lawsuit, which includes the defendants Actelion Pharmaceuticals Ltd., Actelion Pharmaceuticals US, Inc., and Janssen Research & Development, LLC, alleges that these companies acted unlawfully by keeping the generic version of Tracleer, known as bosentan, out of the market. This action reportedly led to higher costs for third-party payors who bought brand-name Tracleer and bosentan. While the defendants deny any wrongdoing, the case has now culminated in a court-approved settlement intended to compensate affected parties.

Who is Eligible for the Settlement?

Individuals and organizations that purchased or reimbursed costs for Tracleer or bosentan from December 29, 2015, to September 6, 2024, in various states including California, Florida, and New York, may be included in the settlement class. However, federal and state government entities and the defendants themselves are excluded from this settlement.

Financial Details and Claims Process

The total settlement fund is valued at $65 million, which is earmarked for eligible class members, administrative costs, attorney fees, and a service award for the representative of the class. Individuals who have valid claims can expect compensation based on the amount and cost of Tracleer or bosentan they purchased. To receive compensation, eligible claimants will need to submit a claim form by August 3, 2026.

Rights and Options for Class Members

Class members have the right to object to the settlement until June 2, 2026. For those interested in voicing their opinions or concerns, details on how to file objections will be made available on the official litigation website. The court intends to hold a fairness hearing on July 1, 2026, to finalize approval of the settlement and related attorney fee requests.

Next Steps and Further Information

For more information regarding the settlement, including a comprehensive overview of how to submit claims or objections, individuals are encouraged to visit www.TracleerLitigation.com or call the helpline at 1-877-354-3839. It is crucial for class members to stay updated on any changes to the settlement timeline or further instructions.

This settlement represents a significant step toward providing relief and compensation to those affected by the pricing practices related to Tracleer and bosentan, and affected parties should ensure they follow the proper channels to claim their rights.